CAR T-Cell Therapy Saved My Life: Robyn's Non-Hodgkin Lymphoma Story | The Patient Story
4,436
Published 2023-04-24
In this conversation, Robyn, a three-time DLBCL survivor, and two top lymphoma specialists, Dr. Tycel Phillips from the City of Hope and Dr. Joshua Brody from Mount Sinai, discuss the latest research and treatment options n the most common subtype of non-Hodgkin lymphoma: diffuse large B-cell lymphoma (DLBCL).
Thank you to Genmab and AbbVie for their support of our patient education program.
Full story & transcript → www.thepatientstory.com/medical-experts/dlbcl-roun…
Join Our Community:
Website : www.thepatientstory.com/
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story
02:06 - What is diffused large B-cell lymphoma.
03:54 - What are the different treatment options for DLBCL?
05:45 - What is the treatment for a patient who relapses in the first 6-12 months?
09:25 - What is CAR T-Cell Therapy?
11:54 - Benefits and challenges of CAR T-Cell Therapy.
13:46 - CAR T-Cell therapy for refractory patients
#cancersurvivor #cancerstories #cancer #thepatientstory #dlbcl #lymsm #nonhodgkinlymphoma #lymphoma #lymphomasurvivor #lymphomaawareness #cancertreatments #cancerresearch
All Comments (3)
-
Had Car t in 2021 had a relapse late 2022, just got singed up for tmCD19-18 which is a new study. Currently scheduled to start treatment in November will let know how I make out.
-
Thank you for updates. I had benamustine and rituxinab in 2018 for cll. Starting to relapse. I doubt I can do car t as I'm older.